^
    22h
    BAT-RAD: Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=47, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2027 --> Feb 2029 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    abiraterone acetate • Xofigo (radium Ra-223 dichloride)
    23h
    AcTFirst: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (clinicaltrials.gov)
    P3, N=940, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Feb 2028 --> Sep 2028
    Trial primary completion date
    |
    HRD (Homologous Recombination Deficiency)
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • 225Ac-vipivotide tetraxetan (AAA817)
    2d
    Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) (clinicaltrials.gov)
    P1/2, N=2, Terminated, Ariceum Therapeutics GmbH | N=50 --> 2 | Trial completion date: Dec 2026 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Dec 2025; Study terminated due to strategic business decisions.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Zynyz (retifanlimab-dlwr) • SOMther (lutetium-177 DOTA satoreotide)
    2d
    A Phase 0 Imaging Trial of [203Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [212Pb]Pb-VMT-α-NET. (PubMed, J Nucl Med)
    [203Pb]Pb-VMT-α-NET appears to be a safe and effective SPECT/CT tracer for imaging NETs larger than 1 cm and for normal organ and tumor radiation dosimetry. The chemically matched 203/212Pb theranostic pair offers the potential for a dosimetry-driven personalized treatment paradigm.
    Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    VMT-𝛼-NET
    4d
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=37, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | N=76 --> 37
    Enrollment closed • Enrollment change
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    9d
    Study With [225Ac]Ac-FL-020 in mCRPC Participants (clinicaltrials.gov)
    P1, N=50, Recruiting, Full-Life Technologies GmbH | N=35 --> 50 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment change • Trial primary completion date • First-in-human
    |
    225Ac-FL-020
    9d
    Low-Count Quantitative SPECT for Men Treated With Radium-223 (clinicaltrials.gov)
    P=N/A, N=38, Not yet recruiting, Washington University School of Medicine | Trial completion date: Nov 2027 --> Mar 2028 | Initiation date: Nov 2025 --> Mar 2026 | Trial primary completion date: Aug 2027 --> Dec 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    15d
    Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=9, Recruiting, First Affiliated Hospital of Fujian Medical University
    New P1/2 trial
    18d
    ACTION-1: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov)
    P3, N=288, Recruiting, RayzeBio, Inc. | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101)
    23d
    Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, Orano Med LLC | Trial completion date: Aug 2027 --> May 2032 | Trial primary completion date: Aug 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + ER positive
    |
    212Pb-DOTAM-GRPR1
    24d
    Radium-223 in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xofigo (radium Ra-223 dichloride)
    24d
    Efficacy of Ra-223 in PSMA PET Optimally Selected Patients (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting | N=54 --> 2 | Trial completion date: May 2028 --> Mar 2027 | Trial primary completion date: May 2026 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)